Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas
- Conditions
- Lymphoma
- Interventions
- Procedure: Stem Cell Collection
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT01329900
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT01319981
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response
- Conditions
- OsteosarcomaLung Metastases
- Interventions
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 2
- Registration Number
- NCT01258634
- Locations
- 🇺🇸
University of Chicago Department of Pediatrics Hematology/Oncology, Chicago, Illinois, United States
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
- Conditions
- Non-Hodgkin's LymphomaBreast Cancer
- Interventions
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Mara Chambers
- Target Recruit Count
- 32
- Registration Number
- NCT01205503
- Locations
- 🇺🇸
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
Tandem Auto-Allo Transplant for Lymphoma
- Conditions
- Lymphoma, Low-GradeT-Cell LymphomaDiffuse, Large B-Cell, LymphomaMantle-Cell LymphomaChronic Lymphocytic LeukemiaLymphoma, Small LymphocyticHodgkin's Lymphoma
- Interventions
- Other: autologous (auto) peripheral blood stem cell transplantationOther: non-myeloablative allogeneic (allo) transplant
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT01181271
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
- Conditions
- Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT01169636
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
- Conditions
- Clear Cell EpendymomaPapillary EpendymomaAnaplastic EpendymomaCellular EpendymomaEpendymomaBrain Ependymoma
- Interventions
- Radiation: 3-Dimensional Conformal Radiation TherapyOther: Clinical ObservationOther: Laboratory Biomarker Analysis
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 479
- Registration Number
- NCT01096368
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸University of Illinois, Chicago, Illinois, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
- Conditions
- Blood Stem Cell Transplant FailureLeukemiaHematologic Malignancies
- Interventions
- Procedure: Stem Cell TransplantationDrug: Mycofenolate mofetil
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 176
- Registration Number
- NCT01010217
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
- Conditions
- Acute Lymphocytic LeukemiaLeukemia
- Interventions
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00968253
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
- Conditions
- LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00958256
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.